Ipamorelin is not a licensed medicine or drug and has not been approved by the MHRA, FDA, or any regulatory authority for human or veterinary use
It is specifically characterized by inflammation, demyelination, and neuronal loss and manifests with a range of neurological symptoms including numbness, tingling, vision impairment, cognitive impairment, and bladder and bowel dysfunction (Tafti et al., 2024)
It causes a variety of uncomfortable or painful symptoms, and can be dangerous in severe cases
While melanotan I has been approved in Australia for highly specialised use, melanotan II has never been assessed by the TGA and its development as a potential medicine was stopped years ago due to safety reasons
The most realistic benefit of TRT is not rapid weight loss, like many other weight loss pharmaceuticals on the market, Honomichl said
Standard practice includes: Baseline thyroid function tests (TSH and free T4) before initiating GLP-1 therapy Repeat testing at 812 weeks after starting treatment or after dose escalation Regular monitoring every 36 months during active weight loss Return to annual monitoring once weight is stable and thyroid function remains consistent Adjustments to levothyroxine dosing may be necessary as weight changes